Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy.

Saison-Ridinger M, DelGiorno KE, Zhang T, Kraus A, French R, Jaquish D, Tsui C, Erikson G, Spike BT, Shokhirev MN, Liddle C, Yu RT, Downes M, Evans RM, Saghatelian A, Lowy AM, Wahl GM.

PLoS One. 2017 Dec 6;12(12):e0189051. doi: 10.1371/journal.pone.0189051. eCollection 2017.

2.

Lgr5 is a marker for fetal mammary stem cells, but is not essential for stem cell activity or tumorigenesis.

Trejo CL, Luna G, Dravis C, Spike BT, Wahl GM.

NPJ Breast Cancer. 2017 Apr 24;3:16. doi: 10.1038/s41523-017-0018-6. eCollection 2017.

3.

Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity.

Wahl GM, Spike BT.

NPJ Breast Cancer. 2017 Apr 19;3:14. doi: 10.1038/s41523-017-0012-z. eCollection 2017.

4.

Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity.

Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, Furnari FB, Vandenberg SR, Rao PN, Wahl GM, Bafna V, Mischel PS.

Nature. 2017 Mar 2;543(7643):122-125. doi: 10.1038/nature21356. Epub 2017 Feb 8.

5.

Establishment of human iPSC-based models for the study and targeting of glioma initiating cells.

Sancho-Martinez I, Nivet E, Xia Y, Hishida T, Aguirre A, Ocampo A, Ma L, Morey R, Krause MN, Zembrzycki A, Ansorge O, Vazquez-Ferrer E, Dubova I, Reddy P, Lam D, Hishida Y, Wu MZ, Esteban CR, O'Leary D, Wahl GM, Verma IM, Laurent LC, Izpisua Belmonte JC.

Nat Commun. 2016 Feb 22;7:10743. doi: 10.1038/ncomms10743.

6.

Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells.

Dravis C, Spike BT, Harrell JC, Johns C, Trejo CL, Southard-Smith EM, Perou CM, Wahl GM.

Cell Rep. 2015 Sep 29;12(12):2035-48. doi: 10.1016/j.celrep.2015.08.040. Epub 2015 Sep 10.

7.

The Trp53 delta proline (Trp53ΔP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development.

Adams CJ, Yu JS, Mao JH, Jen KY, Costes SV, Wade M, Shoemake J, Aina OH, Del Rosario R, Menchavez PT, Cardiff RD, Wahl GM, Balmain A.

Mol Carcinog. 2016 Sep;55(9):1387-96. doi: 10.1002/mc.22377. Epub 2015 Aug 27.

8.

A Critical Examination of the "Bad Luck" Explanation of Cancer Risk.

Rozhok AI, Wahl GM, DeGregori J.

Cancer Prev Res (Phila). 2015 Sep;8(9):762-4. doi: 10.1158/1940-6207.CAPR-15-0229. Epub 2015 Jun 29.

9.

Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy.

Pfefferle AD, Spike BT, Wahl GM, Perou CM.

Breast Cancer Res Treat. 2015 Jan;149(2):425-37. doi: 10.1007/s10549-014-3262-6. Epub 2015 Jan 10.

10.

A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time.

Li YC, Rodewald LW, Hoppmann C, Wong ET, Lebreton S, Safar P, Patek M, Wang L, Wertman KF, Wahl GM.

Cell Rep. 2014 Dec 11;9(5):1946-1958. doi: 10.1016/j.celrep.2014.10.058. Epub 2014 Nov 20.

11.

Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.

Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM.

Cell. 2014 Sep 25;159(1):80-93. doi: 10.1016/j.cell.2014.08.007.

12.

Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat.

Hye Khan MA, Neckář J, Cummens B, Wahl GM, Imig JD.

Cardiovasc Drugs Ther. 2014 Aug;28(4):313-22. doi: 10.1007/s10557-014-6530-0.

PMID:
24842561
13.

CRIPTO/GRP78 signaling maintains fetal and adult mammary stem cells ex vivo.

Spike BT, Kelber JA, Booker E, Kalathur M, Rodewald R, Lipianskaya J, La J, He M, Wright T, Klemke R, Wahl GM, Gray PC.

Stem Cell Reports. 2014 Apr 3;2(4):427-39. doi: 10.1016/j.stemcr.2014.02.010. eCollection 2014 Apr 8.

14.

Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.

Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-Arzayus MI, Brown M, Egan SE, Wahl GM, Rosen JM, Perou CM.

Genome Biol. 2013 Nov 12;14(11):R125. doi: 10.1186/gb-2013-14-11-r125.

15.

AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity.

He G, Zhang YW, Lee JH, Zeng SX, Wang YV, Luo Z, Dong XC, Viollet B, Wahl GM, Lu H.

Mol Cell Biol. 2014 Jan;34(2):148-57. doi: 10.1128/MCB.00670-13. Epub 2013 Nov 4.

16.

Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer.

Rasmussen NR, Wright TM, Brooks SA, Hacker KE, Debebe Z, Sendor AB, Walker MP, Major MB, Green J, Wahl GM, Rathmell WK.

J Biol Chem. 2013 Sep 6;288(36):26301-10. doi: 10.1074/jbc.M113.466086. Epub 2013 Jul 26.

17.

Stem cells and the developing mammary gland.

Makarem M, Spike BT, Dravis C, Kannan N, Wahl GM, Eaves CJ.

J Mammary Gland Biol Neoplasia. 2013 Jun;18(2):209-19. doi: 10.1007/s10911-013-9284-6. Epub 2013 Apr 27. Review.

18.

Paracrine Wnt signaling both promotes and inhibits human breast tumor growth.

Green JL, La J, Yum KW, Desai P, Rodewald LW, Zhang X, Leblanc M, Nusse R, Lewis MT, Wahl GM.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6991-6. doi: 10.1073/pnas.1303671110. Epub 2013 Apr 4.

19.

Use of a molecular genetic platform technology to produce human Wnt proteins reveals distinct local and distal signaling abilities.

Green JL, Bauer M, Yum KW, Li YC, Cox ML, Willert K, Wahl GM.

PLoS One. 2013;8(3):e58395. doi: 10.1371/journal.pone.0058395. Epub 2013 Mar 13.

20.

MDM2, MDMX and p53 in oncogenesis and cancer therapy.

Wade M, Li YC, Wahl GM.

Nat Rev Cancer. 2013 Feb;13(2):83-96. doi: 10.1038/nrc3430. Epub 2013 Jan 10. Review.

21.

What a difference a phosphate makes: life or death decided by a single amino acid in MDM2.

Li YC, Wahl GM.

Cancer Cell. 2012 May 15;21(5):595-6. doi: 10.1016/j.ccr.2012.04.033.

22.

Hypoxia activates tumor suppressor p53 by inducing ATR-Chk1 kinase cascade-mediated phosphorylation and consequent 14-3-3γ inactivation of MDMX protein.

Lee JH, Jin Y, He G, Zeng SX, Wang YV, Wahl GM, Lu H.

J Biol Chem. 2012 Jun 15;287(25):20898-903. doi: 10.1074/jbc.M111.336875. Epub 2012 May 3.

23.

Egg dispersal in the acanthocephalan Acanthocephalus dirus: field data.

Wahl GM, Sparkes TC.

J Parasitol. 2012 Aug;98(4):894-6. doi: 10.1645/GE-3078.1. Epub 2012 Feb 23.

PMID:
22360588
24.

A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer.

Spike BT, Engle DD, Lin JC, Cheung SK, La J, Wahl GM.

Cell Stem Cell. 2012 Feb 3;10(2):183-97. doi: 10.1016/j.stem.2011.12.018.

25.

Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.

Wade M, Li YC, Matani AS, Braun SM, Milanesi F, Rodewald LW, Wahl GM.

Oncogene. 2012 Nov 8;31(45):4789-97. doi: 10.1038/onc.2011.625. Epub 2012 Jan 23.

26.

p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome.

Spike BT, Wahl GM.

Genes Cancer. 2011 Apr;2(4):404-19. doi: 10.1177/1947601911410224.

27.

Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity.

Wang YV, Leblanc M, Fox N, Mao JH, Tinkum KL, Krummel K, Engle D, Piwnica-Worms D, Piwnica-Worms H, Balmain A, Kaushansky K, Wahl GM.

Genes Dev. 2011 Jul 1;25(13):1426-38. doi: 10.1101/gad.2024411.

28.

Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures.

Mizuno H, Spike BT, Wahl GM, Levine AJ.

Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22745-50. doi: 10.1073/pnas.1017001108. Epub 2010 Dec 13.

29.

A stapled p53 helix overcomes HDMX-mediated suppression of p53.

Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL, Wahl GM, Walensky LD.

Cancer Cell. 2010 Nov 16;18(5):411-22. doi: 10.1016/j.ccr.2010.10.024.

30.

Linea alba fasciotomy: a novel alternative in trauma patients with secondary abdominal compartment syndrome.

Duchesne JC, Howell MP, Eriksen C, Wahl GM, Rennie KV, Hastings PE, McSwain NE Jr, Malbrain ML.

Am Surg. 2010 Mar;76(3):312-6.

PMID:
20349663
31.

Red light cameras: do they change driver behavior and reduce accidents?

Wahl GM, Islam T, Gardner B, Marr AB, Hunt JP, McSwain NE, Baker CC, Duchesne J.

J Trauma. 2010 Mar;68(3):515-8. doi: 10.1097/TA.0b013e3181cf7f0e.

PMID:
20220412
32.

The p53 orchestra: Mdm2 and Mdmx set the tone.

Wade M, Wang YV, Wahl GM.

Trends Cell Biol. 2010 May;20(5):299-309. doi: 10.1016/j.tcb.2010.01.009. Epub 2010 Feb 19. Review.

33.

Open-book pelvic fractures with perineal open wounds: a significant morbid combination.

Duchesne JC, Bharmal HM, Dini AA, Islam T, Schmieg RE Jr, Simmons JD, Wahl GM, Davis JA Jr, Krause P, McSwain NE Jr.

Am Surg. 2009 Dec;75(12):1227-33.

PMID:
19999917
34.

Guarding the guardian: Mdmx plays important roles in setting p53 basal activity and determining biological responses in vivo.

Wang YV, Wade M, Wahl GM.

Cell Cycle. 2009 Nov 1;8(21):3443-4. Epub 2009 Nov 6. No abstract available.

35.

The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF-beta-mediated growth regulation.

Ponnamperuma RM, King KE, Elsir T, Glick AB, Wahl GM, Nister M, Weinberg WC.

J Pathol. 2009 Oct;219(2):263-74. doi: 10.1002/path.2600.

36.

Linking the p53 tumour suppressor pathway to somatic cell reprogramming.

Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Izpisúa Belmonte JC.

Nature. 2009 Aug 27;460(7259):1140-4. doi: 10.1038/nature08311. Epub 2009 Aug 9.

37.

Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases.

Wang YV, Leblanc M, Wade M, Jochemsen AG, Wahl GM.

Cancer Cell. 2009 Jul 7;16(1):33-43. doi: 10.1016/j.ccr.2009.05.008.

38.

The changing face of trauma: New Orleans before and after Hurricane Katrina.

Wahl GM, Marr AB, Brevard SB, Weintraub SL, Hunt JP, McSwain NE, Duchesne JC, Baker CC.

Am Surg. 2009 Apr;75(4):284-6.

PMID:
19385285
39.

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Wade M, Wahl GM.

Mol Cancer Res. 2009 Jan;7(1):1-11. doi: 10.1158/1541-7786.MCR-08-0423. Review.

40.

BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death.

Wade M, Rodewald LW, Espinosa JM, Wahl GM.

Cell Cycle. 2008 Jul 1;7(13):1973-82.

41.

How does leflunomide modulate the immune response in rheumatoid arthritis?

Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Kirschbaum BJ.

BioDrugs. 1999 Oct;12(4):301-15.

PMID:
18031184
42.

Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation.

Wang YV, Wade M, Wong E, Li YC, Rodewald LW, Wahl GM.

Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12365-70. Epub 2007 Jul 17.

43.

MDM2 and MDM4: p53 regulators as targets in anticancer therapy.

Toledo F, Wahl GM.

Int J Biochem Cell Biol. 2007;39(7-8):1476-82. Epub 2007 Apr 8. Review.

44.

Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression.

Toledo F, Lee CJ, Krummel KA, Rodewald LW, Liu CW, Wahl GM.

Mol Cell Biol. 2007 Feb;27(4):1425-32. Epub 2006 Dec 11.

45.

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.

Toledo F, Wahl GM.

Nat Rev Cancer. 2006 Dec;6(12):909-23. Review.

PMID:
17128209
46.

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM.

Cancer Res. 2006 Oct 1;66(19):9339-44. Epub 2006 Sep 21. No abstract available.

47.

Hdmx modulates the outcome of p53 activation in human tumor cells.

Wade M, Wong ET, Tang M, Stommel JM, Wahl GM.

J Biol Chem. 2006 Nov 3;281(44):33036-44. Epub 2006 Aug 13.

48.

RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses.

Toledo F, Liu CW, Lee CJ, Wahl GM.

Nucleic Acids Res. 2006 Jul 26;34(13):e92.

49.

c-Myc, genome instability, and tumorigenesis: the devil is in the details.

Wade M, Wahl GM.

Curr Top Microbiol Immunol. 2006;302:169-203. Review.

PMID:
16620029
50.

A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.

Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM.

Cancer Cell. 2006 Apr;9(4):273-85.

Supplemental Content

Support Center